Sun Pharma Launches Taro-Methylphenidate ER for ADHD
Mumbai, India and Brampton, Ontario, Canada, September 21, 2026 Sun Pharmaceutical Industries Limited (Sun Pharma) has announced the commercial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Mumbai, India and Brampton, Ontario, Canada, September 21, 2026 Sun Pharmaceutical Industries Limited (Sun Pharma) has announced the commercial...
Basel, Switzerland, September 21, 2026 Roche has announced that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL) for...
CRYSTAL LAKE, Ill. — September 14, 2026 Aptar Pharma and Massachusetts General Hospital (MGH) announced a research collaboration led...
TEL AVIV, Israel — September 14, 2026 Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA)...
MONMOUTH JUNCTION, N.J. — September 14, 2026 Tris Pharma, Inc. announced the availability of a new 30-count bottle size...
Crystal Lake, Illinois — September 7, 2026 Aptar Pharma announced a collaboration with Aceso Therapeutics to advance development activities...
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
PRINCETON, New Jersey, August 20, 2026 UroGen Pharma Ltd. announced a strategic collaboration and investment agreement with IntraGel Therapeutics,...
Mequon, Wisconsin, August 17, 2026 Vector Science and Therapeutics Corp. has entered into an amended and restated exclusive license...
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
